Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PF 07209960

Next Previous
Drug Profile

PF 07209960

Alternative Names: PF-07209960

Latest Information Update: 04 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Antineoplastics; Immunotherapies; Interleukins; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 20 Jul 2023 Pfizer terminates a phase I trial for Solid tumours (Metastatic disease, Late-stage disease, Second-line therapy and greater) in US (Unspecified route) due to pause in the development of PF 07209960 based on internal business decision (NCT04628780) (EudraCT2021-004587-10)
  • 26 May 2023 Pfizer completes a phase I trial for Solid tumours (Metastatic disease, Late-stage disease, Second-line therapy and greater) in US (Unspecified route) (NCT04628780)
  • 02 May 2023 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (unspecified route) (Pfizer pipeline, August 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top